212 related articles for article (PubMed ID: 26751641)
1. Assembly of methylated KDM1A and CHD1 drives androgen receptor-dependent transcription and translocation.
Metzger E; Willmann D; McMillan J; Forne I; Metzger P; Gerhardt S; Petroll K; von Maessenhausen A; Urban S; Schott AK; Espejo A; Eberlin A; Wohlwend D; Schüle KM; Schleicher M; Perner S; Bedford MT; Jung M; Dengjel J; Flaig R; Imhof A; Einsle O; Schüle R
Nat Struct Mol Biol; 2016 Feb; 23(2):132-9. PubMed ID: 26751641
[TBL] [Abstract][Full Text] [Related]
2. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
[TBL] [Abstract][Full Text] [Related]
3. CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer.
Burkhardt L; Fuchs S; Krohn A; Masser S; Mader M; Kluth M; Bachmann F; Huland H; Steuber T; Graefen M; Schlomm T; Minner S; Sauter G; Sirma H; Simon R
Cancer Res; 2013 May; 73(9):2795-805. PubMed ID: 23492366
[TBL] [Abstract][Full Text] [Related]
4. Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer.
Todorova K; Metodiev MV; Metodieva G; Mincheff M; Fernández N; Hayrabedyan S
Horm Cancer; 2017 Feb; 8(1):28-48. PubMed ID: 28050800
[TBL] [Abstract][Full Text] [Related]
5. Relation of ETS transcription factor family member ERG, androgen receptor and topoisomerase 2β expression to TMPRSS2-ERG fusion status in prostate cancer.
Kolar Z; Burdova A; Jamaspishvili T; Bouchal J; Kucerova R; Bienova M; Kral M; Student V
Neoplasma; 2014; 61(1):9-16. PubMed ID: 24195515
[TBL] [Abstract][Full Text] [Related]
6. KDM1A triggers androgen-induced miRNA transcription via H3K4me2 demethylation and DNA oxidation.
Yang S; Zhang J; Zhang Y; Wan X; Zhang C; Huang X; Huang W; Pu H; Pei C; Wu H; Huang Y; Huang S; Li Y
Prostate; 2015 Jun; 75(9):936-46. PubMed ID: 25728837
[TBL] [Abstract][Full Text] [Related]
7. ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen Receptor.
Mounir Z; Korn JM; Westerling T; Lin F; Kirby CA; Schirle M; McAllister G; Hoffman G; Ramadan N; Hartung A; Feng Y; Kipp DR; Quinn C; Fodor M; Baird J; Schoumacher M; Meyer R; Deeds J; Buchwalter G; Stams T; Keen N; Sellers WR; Brown M; Pagliarini RA
Elife; 2016 May; 5():. PubMed ID: 27183006
[TBL] [Abstract][Full Text] [Related]
8.
Jillson LK; Rider LC; Rodrigues LU; Romero L; Karimpour-Fard A; Nieto C; Gillette C; Torkko K; Danis E; Smith EE; Nolley R; Peehl DM; Lucia MS; Costello JC; Cramer SD
Mol Cancer Res; 2021 Jul; 19(7):1123-1136. PubMed ID: 33846123
[TBL] [Abstract][Full Text] [Related]
9. Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma.
Wang L; Williamson SR; Zhang S; Huang J; Montironi R; Davison DD; Wang M; Yao JL; Lopez-Beltran A; Osunkoya AO; MacLennan GT; Baldridge LA; Du X; Cheng L
Mol Carcinog; 2015 Sep; 54(9):900-7. PubMed ID: 24777847
[TBL] [Abstract][Full Text] [Related]
10. CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis.
Augello MA; Liu D; Deonarine LD; Robinson BD; Huang D; Stelloo S; Blattner M; Doane AS; Wong EWP; Chen Y; Rubin MA; Beltran H; Elemento O; Bergman AM; Zwart W; Sboner A; Dephoure N; Barbieri CE
Cancer Cell; 2019 Apr; 35(4):603-617.e8. PubMed ID: 30930119
[TBL] [Abstract][Full Text] [Related]
11. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.
Yu J; Yu J; Mani RS; Cao Q; Brenner CJ; Cao X; Wang X; Wu L; Li J; Hu M; Gong Y; Cheng H; Laxman B; Vellaichamy A; Shankar S; Li Y; Dhanasekaran SM; Morey R; Barrette T; Lonigro RJ; Tomlins SA; Varambally S; Qin ZS; Chinnaiyan AM
Cancer Cell; 2010 May; 17(5):443-54. PubMed ID: 20478527
[TBL] [Abstract][Full Text] [Related]
12. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
[TBL] [Abstract][Full Text] [Related]
13. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.
Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B
Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739
[TBL] [Abstract][Full Text] [Related]
14. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.
Winnes M; Lissbrant E; Damber JE; Stenman G
Oncol Rep; 2007 May; 17(5):1033-6. PubMed ID: 17390040
[TBL] [Abstract][Full Text] [Related]
15. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer.
Björkman M; Iljin K; Halonen P; Sara H; Kaivanto E; Nees M; Kallioniemi OP
Int J Cancer; 2008 Dec; 123(12):2774-81. PubMed ID: 18798265
[TBL] [Abstract][Full Text] [Related]
16. An AR-ERG transcriptional signature defined by long-range chromatin interactomes in prostate cancer cells.
Zhang Z; Chng KR; Lingadahalli S; Chen Z; Liu MH; Do HH; Cai S; Rinaldi N; Poh HM; Li G; Sung YY; Heng CL; Core LJ; Tan SK; Ruan X; Lis JT; Kellis M; Ruan Y; Sung WK; Cheung E
Genome Res; 2019 Feb; 29(2):223-235. PubMed ID: 30606742
[TBL] [Abstract][Full Text] [Related]
17. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription.
Metzger E; Wissmann M; Yin N; Müller JM; Schneider R; Peters AH; Günther T; Buettner R; Schüle R
Nature; 2005 Sep; 437(7057):436-9. PubMed ID: 16079795
[TBL] [Abstract][Full Text] [Related]
18. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.
Tomlins SA; Laxman B; Dhanasekaran SM; Helgeson BE; Cao X; Morris DS; Menon A; Jing X; Cao Q; Han B; Yu J; Wang L; Montie JE; Rubin MA; Pienta KJ; Roulston D; Shah RB; Varambally S; Mehra R; Chinnaiyan AM
Nature; 2007 Aug; 448(7153):595-9. PubMed ID: 17671502
[TBL] [Abstract][Full Text] [Related]
19. Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin.
Flajollet S; Tian TV; Flourens A; Tomavo N; Villers A; Bonnelye E; Aubert S; Leroy X; Duterque-Coquillaud M
Mol Cancer Res; 2011 Jul; 9(7):914-24. PubMed ID: 21669963
[TBL] [Abstract][Full Text] [Related]
20. Prostatic adenocarcinoma CNS parenchymal and dural metastases: alterations in ERG, CHD1 and MAP3K7 expression.
Ormond DR; Kleinschmidt-DeMasters BK; Cavalcante D; Smith EE; Cramer SD; Lucia MS
J Neurooncol; 2019 Apr; 142(2):319-325. PubMed ID: 30656528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]